| 1. |
|
|
| 2. |
- Vikerfors, A, et al.
(författare)
-
Studies of microparticles in patients with the antiphospholipid syndrome (APS)
- 2012
-
Ingår i: Lupus. - : SAGE Publications. - 1477-0962 .- 0961-2033. ; 21:7, s. 802-805
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives: To study circulating platelet, monocyte and endothelial microparticles (PMPs, MMPs and EMPs) in patients with antiphospholipid syndrome (APS) in comparison with healthy controls. Material and method: Fifty-two patients with APS and 52 healthy controls were investigated. MPs were measured on a flow cytometer (Beckman Gallios) and defined as particles sized < 1.0 µm, negative to phalloidin, positive to lactadherin and positive to either CD42a (PMPs), CD144 (EMPs) or CD14 (MMPs). Exposure of CD142 (TF) was measured on CD144 positive MPs. Results: Total number of MPs (i.e. lactadherin positive particles) was higher in APS patients versus controls ( p < 0.001). An increased number of EMPs ( p < 0.001), increased TF-positive EMPs ( p < 0.001) and increased MMPs ( p < 0.001) were also observed. PMP numbers did not differ between the groups. None of the MP types differed in numbers between obstetric and thrombotic APS patients. Conclusion: We observed a high number of EMPs expressing TF in APS patients. The numbers of MMPs and total EMPs were also higher as compared with healthy controls but in contrast to previous reports, the number of PMPs did not differ between groups.
|
|
| 3. |
- Agren, A, et al.
(författare)
-
In response
- 2014
-
Ingår i: Anesthesia and analgesia. - 1526-7598. ; 119:6, s. 1453-1453
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Fugelstad, A, et al.
(författare)
-
Long-term mortality and causes of death among hospitalized Swedish drug users
- 2014
-
Ingår i: Scandinavian journal of public health. - : SAGE Publications. - 1651-1905 .- 1403-4948. ; 42:4, s. 364-369
-
Tidskriftsartikel (refereegranskat)abstract
- Aim: To study long-term mortality and causes of death in a cohort of drug users in relation to main type of drug use and HIV-status. Methods: A total of 1640 hospitalized drug users in Stockholm was followed up from 1985 to the end of 2007. The mortality was compared with the general Swedish population and hazard ratios (HR) for the main risk indicators were calculated. The causes of death were studied, using information from death certificates. Results: 630 persons died during the observation period. The Standard Mortality Ratio (SMR) was 16.1 (males 13.8, females 18.5). The crude mortality rate was 2.0 % (males 2.2% and females 1.5%). The mortality rate was higher in heroin users than among amphetamine users, HR 1.96, controlled for age and other risk factors. The mortality rate among individuals infected with the human immunodeficiency virus (HIV) was high (4.9 %), HR 2.64, compared with HIV-negative individuals. Most of the deaths were from other causes than acquired immune deficiency syndrome. One-third of deaths (227) were caused by heroin intoxication. The number of deaths from HIV-related causes decreased after 1996, when highly active anti-retroviral therapy was introduced. In all, there were 92 HIV-related deaths. Deaths from natural causes increased during the observation period. The SMR was highest for cardiovascular and gastrointestinal diseases. The results indicate a correlation between amphetamine use and death from cerebral haemorrhage. A high proportion of natural deaths were alcohol-related. Conclusions: The death rate among illicit drug users was persistently high. Alcohol consumption was a contributing factor to premature death.
|
|
| 10. |
|
|
